[The therapeutic activity of stepronin in viral hepatitis].
The therapeutic effect of stepronin in 5% glucosate solution has been evaluated in 55/110 viral hepatitis cases (10/55 of A type, 37/55 of B type and 8/55 of nA type nB type), versus other cases (8/55 of A type, 40/55 of B type of 7/55 of nA nB type), treated with 5% glucose solution only. In 18/110 viral hepatitis case of A type, final results with the two different therapies have not shown statistically significantly changes and were comparable. Particularly favourable, in the patients treated, the results obtained in viral hepatitis of B type and nA nB type, were very significant statistically at the end of therapy. In particular, the 2 transaminasic activities had a beneficial influence. Tolerance was very good: only in there cases nettlerash was observed and therapy interrupted in one patient. Therefore the validity of this sulphydryl pro-drug in the treatment of acute viral hepatitis of B and nA and nB type is confirmed.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001663:Bilirubin / Q000097:blood; D002648:Child; D002986:Clinical Trials as Topic; D005260:Female; D005947:Glucose / Q000627:therapeutic use; D005998:Glycine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006525:Hepatitis, Viral, Human / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013440:Sulfides; D013876:Thiophenes; D000637:Transaminases / Q000378:metabolism
D013440:Sulfides; D013876:Thiophenes; C035227:stepronin; D000637:Transaminases; D005947:Glucose; D001663:Bilirubin; D005998:Glycine
Studio sull'attività terapeutica di stepronin in corso di epatite virale.